Elevated plasma levels of high mobility group box protein 1 in patients with HIV-1 infection

AIDS

Volumn 21, Issue 7, 2007, Pages 869-871

  Nowak, Piotr ^a   Barqasho, Babilonia ^a   Sönnerborg, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN;

ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOREACTIVITY; IMMUNOREGULATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; VIRUS REPLICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HMGB1 PROTEIN; HUMANS; MALE; VIRAL LOAD;

EID: 34147140961     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3280b079b6     Document Type: Article

References (18)

1. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5:331-342.
2. Ulloa L, Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 2006; 17:189-201.
3. Appay V, Boutboul F, Autran B. The HIV infection and immune activation: "to fight and burn". Curr Infect Dis Rep 2005; 7:473-479.
4. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:1881-1888.
5. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4R T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
6. Aleman S, Pehrson P, Sonnerborg A. Kinetics of beta- chemokine levels during anti-HIV therapy. Antivir Ther 1999; 4:109-115.
7. Naghavi MH, Nowak P, Andersson J, Sonnerborg A, Yang H, Tracey KJ, Vahlne A. Intracellular high mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed transcription in a promoter- and cell-specific manner. Virology 2003; 314:179-189.
8. Nowak P, Barqasho B, Treutiger CJ, Harris HE, Tracey KJ, Andersson J, Sonnerborg A. HMGB1 activates replication of latent HIV-1 in a monocytic cell-line, but inhibits HIV-1 replication in primary macrophages. Cytokine 2006; 34:17-23.
9. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53:1-112.
10. Yamada S, Yakabe K, Ishii J, Imaizumi H, Maruyama I. New high mobility group box 1 assay system. Clin Chim Acta 2006; 372:173-178.
11. Tagami K, Yujiri T, Tanimura A, Mitani N, Nakamura Y, Ariyoshi K, et al. Elevation of serum high-mobility group box 1 protein during granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilisation. Br J Haematol 2006; 135:567-569.
12. Yasuda T, Ueda T, Takeyama Y, Shinzeki M, Sawa H, Nakajima T, et al. Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Pancreas 2006; 33:359-363.
13. Hatada T, Wada H, Nobori T, Okabayashi K, Maruyama K, Abe Y, et al. Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005; 94:975-979.
14. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418:191-195.
15. Plymale DR, Tang DS, Comardelle AM, Fermin CD, Lewis DE, Garry RF. Both necrosis and apoptosis contribute to HIV-1-induced killing of CD4 cells. AIDS 1999; 13:1827-1839.
16. Wang H, Ward MF, Fan XG, Sama AE, Li W. Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol 2006; 19:3-9.
17. Chu JJ, Ng ML. The mechanism of cell death during West Nile virus infection is dependent on initial infectious dose. J Gen Virol 2003; 84:3305-3314.
18. Mantell LL, Parrish WR, Ulloa L. Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock 2006; 25:4-11.